New hope for rare skin condition: dupilumab trial launches
NCT ID NCT04600362
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study tests if dupilumab, a drug already approved for eczema, can help people with nummular eczema—a chronic, itchy skin disease. About 70 adults with moderate-to-severe symptoms will receive either dupilumab or a placebo. The goal is to see if the drug reduces skin inflammation and improves quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NUMMULAR ECZEMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Klinikum re. Isar Dermatology
München, Bavaria, 81675, Germany
Conditions
Explore the condition pages connected to this study.